Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis To Start Phase III Trial For Cancer Drug Everolimus

This article was originally published in PharmAsia News

Executive Summary

The Tokyo based subsidiary of Swiss drug maker Novartis Pharma plans to start final phase trial this summer for cancer drug everolimus (RAD001) to treat stomach cancer. A Phase II trial conducted in Japan showed positive results. Among 50 patients, 55 percent showed effectiveness in constraining cancerous growth and 45 percent showed effectiveness in shrinking tumor size. Although some patients developed side effects of stomatitic symptoms, the company viewed the results promising towards a product commercialization and decided to start the Phase III trial. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069890

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel